{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:23:17Z","timestamp":1780485797624,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This retrospective, real-world (RW) study utilizing propensity score matching investigated tumor lysis syndrome (TLS)-related mortalities following anti-hyperuricemic (HU) monotherapy (allopurinol vs. rasburicase) in hematological malignancies. The study aim was to determine if a significant difference exists in the proportion of TLS-associated mortalities in hematological malignancy patients who received either rasburicase or allopurinol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following random selection of patient cases of rasburicase or allopurinol monotherapy, 141 in each group were PS-matched for TLS risk using 11 predictive covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Rasburicase-treated patients had significantly lower TLS-associated mortality (2.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) vs. 7.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following successful PS matching of TLS-risk factors, this study suggests rasburicase statistically significantly reduces TLS-associated mortalities compared to allopurinol.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-025-10090-y","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:52:42Z","timestamp":1762995162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-434X","authenticated-orcid":false,"given":"Mitchell Stuart","family":"Cairo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Ray","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Drea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"10","key":"10090_CR1","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","volume":"97","author":"SC Goldman","year":"2001","unstructured":"Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97(10):2998\u20133003","journal-title":"Blood"},{"key":"10090_CR2","doi-asserted-by":"publisher","first-page":"9684909","DOI":"10.1155\/2017\/9684909","volume":"2017","author":"Y Belay","year":"2017","unstructured":"Y Belay K Yirdaw B Enawgaw 2017 Tumor lysis syndrome in patients with hematological malignancies J Oncol 2017 9684909","journal-title":"J Oncol"},{"issue":"Suppl 1","key":"10090_CR3","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.3816\/CLM.2002.s.012","volume":"3","author":"MS Cairo","year":"2002","unstructured":"MS Cairo 2002 Prevention and treatment of hyperuricemia in hematological malignancies Clin Lymphoma 3 Suppl 1 S26\u201331","journal-title":"Clin Lymphoma"},{"issue":"19","key":"10090_CR4","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH (2011) The tumor lysis syndrome. N Engl J Med 364(19):1844\u20131854","journal-title":"N Engl J Med"},{"issue":"3","key":"10090_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/20009666.2020.1761185","volume":"10","author":"I Puri","year":"2020","unstructured":"Puri I, Sharma D, Gunturu KS, Ahmed AA (2020) Diagnosis and management of tumor lysis syndrome. J Community Hosp Intern Med Perspect 10(3):269\u2013272","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10090_CR6","doi-asserted-by":"publisher","unstructured":"Williams SS, Killeen AA (2019) Tumor lysis syndrome. Arch Pathol Lab Med 143(3)386\u2013393.\u00a0https:\/\/doi.org\/10.5858\/arpa.2017-0278-RS","DOI":"10.5858\/arpa.2017-0278-RS"},{"issue":"5","key":"10090_CR7","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/biomedicines10051012","volume":"10","author":"G Lupusoru","year":"2022","unstructured":"G Lupusoru I Ailincai G Fratila O Ungureanu A Andronesi M Lupusoru  2022 Tumor lysis syndrome: an endless challenge in onco-nephrology Biomedicines 10 5 1012","journal-title":"Biomedicines"},{"key":"10090_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V120.21.238.238","volume":"120","author":"MS Cairo","year":"2012","unstructured":"MS Cairo SC Thompson LS Stern SA Sherman 2012 Incidence of treatment-related, laboratory and clinical tumor lysis syndrome Blood 120 238","journal-title":"Blood"},{"key":"10090_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-75","volume":"5","author":"A McBride","year":"2012","unstructured":"McBride A, Westervelt P (2012) Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol 5:75","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10090_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","volume":"95","author":"SC Howard","year":"2016","unstructured":"Howard SC, Trifilio S, Gregory TK, Baxter N, McBride A (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann Hematol 95(4):563\u2013573","journal-title":"Ann Hematol"},{"issue":"7","key":"10090_CR11","first-page":"705","volume":"8","author":"A McBride","year":"2017","unstructured":"A McBride S Trifilio N Baxter TK Gregory SC Howard 2017 Managing tumor lysis syndrome in the era of novel cancer therapies J Adv Pract Oncol 8 7 705\u2013720","journal-title":"J Adv Pract Oncol"},{"key":"10090_CR12","doi-asserted-by":"publisher","unstructured":"Howard SC, Avagyan A, Workeneh B, Pui, C-H (2024) Tumour lysis syndrome. Nat Rev Dis Primers\u00a010(1):58.\u00a0https:\/\/doi.org\/10.1038\/s41572-024-0052-w","DOI":"10.1038\/s41572-024-0052-w"},{"key":"10090_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102603","volume":"120","author":"AJ Perissinotti","year":"2023","unstructured":"AJ Perissinotti MR Bishop J Bubalo MB Geyer A Goodrich SC Howard J Kula S Mandayam MS Cairo C-H Pui 2023 Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel Cancer Treat Rev 120 102603PMID: 37579533","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"10090_CR14","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1182\/blood.V124.21.4862.4862","volume":"124","author":"R Pathak","year":"2014","unstructured":"R Pathak S Giri MR Aryal P Karmacharya P Thapaliya AA Donato 2014 Predictors of in-hospital mortality in tumor lysis syndrome Blood 124 21 4862","journal-title":"Blood"},{"issue":"1","key":"10090_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"MS Cairo M Bishop 2004 Tumour lysis syndrome: new therapeutic strategies and classification Br J Haematol 127 1 3 11","journal-title":"Br J Haematol"},{"issue":"16","key":"10090_CR16","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"B Coiffier A Altman CH Pui A Younes MS Cairo 2008 Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review J Clin Oncol 26 16 2767 2778","journal-title":"J Clin Oncol"},{"issue":"4","key":"10090_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"MS Cairo B Coiffier A Reiter A Younes 2010 Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus Br J Haematol 149 4 578 586","journal-title":"Br J Haematol"},{"issue":"1","key":"10090_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3324\/haematol.12327","volume":"93","author":"J Hochberg","year":"2008","unstructured":"J Hochberg MS Cairo 2008 Tumor lysis syndrome: current perspective Haematologica 93 1 9 13","journal-title":"Haematologica"},{"issue":"10","key":"10090_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1517\/14712598.8.10.1595","volume":"8","author":"J Hochberg","year":"2008","unstructured":"J Hochberg MS Cairo 2008 Rasburicase: future directions in tumor lysis management Expert Opin Biol Ther 8 10 1595 1604","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10090_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.clml.2016.11.003","volume":"17","author":"MS Cairo","year":"2017","unstructured":"MS Cairo S Thompson K Tangirala MT Eaddy 2017 A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome Clin Lymphoma Myeloma Leuk 17 3 173 178","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10090_CR21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124058","volume":"134","author":"KL Martens","year":"2019","unstructured":"Martens KL, Khalighi PR, Li S, White AA, Silgard E, Frieze D (2019) Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Blood 134:4674","journal-title":"Blood"},{"issue":"14","key":"10090_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1093\/eurheartj\/ehr031","volume":"32","author":"G Heinze","year":"2011","unstructured":"Heinze G, J\u00fcni P (2011) An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 32(14):1704\u20131708. https:\/\/doi.org\/10.1093\/eurheartj\/ehr031","journal-title":"Eur Heart J"},{"key":"10090_CR23","doi-asserted-by":"publisher","unstructured":"Hansen BB, Bowers J (2008) Covariate balance in simple, stratified and clustered comparative studies. Stat Sci\u00a023(2):219\u201336.\u00a0https:\/\/doi.org\/10.1214\/08-STS254\u00a0Available via JSTOR: https:\/\/www.jstor.org\/stable\/27645895","DOI":"10.1214\/08-STS254"},{"key":"10090_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v030.i09","volume":"30","author":"S Iacus","year":"2009","unstructured":"S Iacus G King G Porro 2009 CEM: software for coarsened exact matching J Stat Softw 30 1 27","journal-title":"J Stat Softw"},{"issue":"27","key":"10090_CR25","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","volume":"28","author":"J Cortes","year":"2010","unstructured":"J Cortes JO Moore RT Maziarz M Wetzler M Craig J Matous  2010 Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2013results of a multicenter phase III study J Clin Oncol 28 27 4207 4213","journal-title":"J Clin Oncol"},{"issue":"3","key":"10090_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.12542","volume":"163","author":"PJ Galardy","year":"2013","unstructured":"PJ Galardy J Hochberg SL Perkins L Harrison S Goldman MS Cairo 2013 Rasburicase in the prevention of laboratory\/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children\u2019s Oncology Group report Br J Haematol 163 3 365 372","journal-title":"Br J Haematol"},{"key":"10090_CR27","doi-asserted-by":"crossref","unstructured":"Cairo MS, Thompson S, Tangirala K, Eaddy MT (2017) A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma Myeloma Leuk 17(3):173-8","DOI":"10.1016\/j.clml.2016.11.003"},{"key":"10090_CR28","unstructured":"Gallagher J (2013) Representing the \u2018inconvenient to select\u2019 \u2013 the greatest data-collection challenge. Presentation at European Pharmaceutical Market Research Association conference (EphMRA), London. htttps:\/\/doi.org\/10.13140\/2.1.3650.6241"},{"key":"10090_CR29","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL et al (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas. V.2.2023 [Internet]. National Comprehensive Cancer Network (NCCN). Available from:\u00a0https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10090-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10090-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:33:05Z","timestamp":1765949585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10090-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10090"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10090-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Providing this information is not applicable. This manuscript is based on previously existing observational, anonymized data, and the research did not involve any new interventional studies of human or animal subjects performed by any of the authors. This retrospective study used deidentified data, and no individually identifiable health information was collected. Such studies are exempt, according to 45CFR46 regarding existing data and no identifiers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Yvonne Barnes, Christopher Clark and Edward Drea are employed by Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This material was presented in part by the authors as posters, including at the Annual Meeting of the Society of Hematologic Oncology, September 2022, Houston, TX, USA; at the Annual Meeting and Exposition of the American Society of Hematology, December 2022, New Orleans, LA, USA; and at the European Society for Medical Oncology (ESMO), Madrid, Spain, October 20\u201324, 2023.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}}],"article-number":"1054"}}